Axil Brands, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q4 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Axil Brands, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q4 2016 to Q2 2024.
  • Axil Brands, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending May 31, 2024 was $226K, a 62% decline year-over-year.
  • Axil Brands, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending May 31, 2024 was $1.78M, a 13.3% decline year-over-year.
  • Axil Brands, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $1.78M, a 13.3% decline from 2022.
  • Axil Brands, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $2.06M.
  • Axil Brands, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$183K, a 38.6% increase from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.78M $226K -$369K -62% Mar 1, 2024 May 31, 2024 10-K 2024-08-15
Q1 2024 $2.15M -$46.3K -$268K -121% Dec 1, 2023 Feb 29, 2024 10-Q 2024-04-09
Q4 2023 $2.42M $1.38M +$395K +39.9% Sep 1, 2023 Nov 30, 2023 10-Q 2024-01-04
Q3 2023 $2.03M $220K -$29.8K -11.9% Jun 1, 2023 Aug 31, 2023 8-K 2023-10-13
Q2 2023 $2.06M $596K +$691K Mar 1, 2023 May 31, 2023 10-K 2024-08-15
Q1 2023 $1.36M $222K +$321K Dec 1, 2022 Feb 28, 2023 10-Q 2024-04-09
Q4 2022 $1.04M $988K +$960K +3403% Sep 1, 2022 Nov 30, 2022 10-Q 2024-01-04
Q3 2022 $83.4K $250K +$266K Jun 1, 2022 Aug 31, 2022 8-K 2023-10-13
Q2 2022 -$183K -$95.8K +$79.4K +45.3% Mar 1, 2022 May 31, 2022 10-K 2023-08-21
Q1 2022 -$262K -$99.3K +$7.15K +6.71% Dec 1, 2021 Feb 28, 2022 10-Q 2023-04-12
Q4 2021 -$269K $28.2K -$24.9K -46.9% Sep 1, 2021 Nov 30, 2021 10-Q 2023-01-10
Q3 2021 -$245K -$16K +$53.2K +76.8% Jun 1, 2021 Aug 31, 2021 10-Q 2022-10-12
Q2 2021 -$298K -$175K -$175K -94564% Mar 1, 2021 May 31, 2021 10-K 2022-08-25
Q1 2021 -$123K -$106K -$64.9K -156% Dec 1, 2020 Feb 28, 2021 10-Q 2022-04-11
Q4 2020 -$58K $53.1K +$83.5K Sep 1, 2020 Nov 30, 2020 10-Q 2022-01-13
Q3 2020 -$141K -$69.3K +$31.3K +31.2% Jun 1, 2020 Aug 31, 2020 10-Q 2021-10-13
Q2 2020 -$173K -$185 -$5.12K -104% Mar 1, 2020 May 31, 2020 10-K 2021-08-30
Q1 2020 -$168K -$41.6K -$38K -1066% Dec 1, 2019 Feb 29, 2020 10-Q 2021-04-14
Q4 2019 -$130K -$30.4K +$27.7K +47.7% Sep 1, 2019 Nov 30, 2019 10-Q 2021-01-12
Q3 2019 -$157K -$101K -$7.31K -7.83% Jun 1, 2019 Aug 31, 2019 10-Q 2020-10-07
Q2 2019 -$150K $4.94K +$6.54K Mar 1, 2019 May 31, 2019 10-K 2020-08-21
Q1 2019 -$157K -$3.57K +$109K +96.8% Dec 1, 2018 Feb 28, 2019 10-Q 2020-04-07
Q4 2018 -$266K -$58K +$43.3K +42.7% Sep 1, 2018 Nov 30, 2018 10-Q 2020-01-07
Q3 2018 -$309K -$93.3K +$33.4K +26.4% Jun 1, 2018 Aug 31, 2018 10-Q 2019-10-02
Q2 2018 -$343K -$1.6K Mar 1, 2018 May 31, 2018 10-K/A 2019-07-19
Q1 2018 -$113K -$3.24K -2.96% Dec 1, 2017 Feb 28, 2018 10-Q 2019-04-10
Q4 2017 -$101K +$9.14K +8.28% Sep 1, 2017 Nov 30, 2017 10-Q 2019-01-14
Q3 2017 -$127K Jun 1, 2017 Aug 31, 2017 10-Q 2018-10-12
Q1 2017 -$110K Dec 1, 2016 Feb 28, 2017 10-Q 2018-04-13
Q4 2016 -$110K Sep 1, 2016 Nov 30, 2016 10-Q 2018-01-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.